Home

Karen Prange

CIK 1566083 · EVP&CEO Gl.AH.Med.Den.Sur.Grp · last filed 2026-06-05

Karen Prange is an EVP&CEO Gl.AH.Med.Den.Sur.Grp who has filed 59 SEC Form 4 insider transactions across 8 companies since 2013. The most recent filing, for OM, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$1.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.11M

Companies

8

Total Filings

59

Lifetime Open-Market Net

-$1.24M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OM Director 29,334 $4.72 $138.5K $0 2 2026-06-05
ATRC Director 26,373 $39.75 $1.05M -$352.6K 11 2026-05-22
EMBC Director 64,581 $3.59 $231.8K $0 5 2026-02-13
NEVRO CORP (NVRO) Delisted Director 0 $5.84 $0 $0 6 2025-04-03
ViewRay, Inc. (VRAY) Delisted Director 46,399 $0.03 $1.2K $91.2K 5 2023-07-21
CANTEL MEDICAL CORP (CMD) Delisted Director 0 $80.37 $0 $0 2 2021-06-02
HSIC EVP&CEO Gl.AH.Med.Den.Sur.Grp 80,200 $85.71 $6.87M $0 3 2018-03-06
BSX SVP&Pres, Uro & Pelvic Health 39,395 $46.06 $1.81M -$976.2K 20 2016-03-08

Recent Filings

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-05 OM Grant (A) +10,667 $0 EDGAR
2026-05-22 ATRC Sell (S) −3,000 -$86.0K EDGAR
2026-05-20 ATRC Notice (144) −3,000 -$86.4K EDGAR
2026-05-20 ATRC Grant (A) +6,144 $0 EDGAR
2026-02-13 EMBC Grant (A) +22,841 $0 EDGAR
2026-01-12 OM Grant (A) +18,667 $0 EDGAR
2025-05-21 ATRC Grant (A) +5,401 $0 EDGAR
2025-04-03 NEVRO CORP (NVRO) Delisted Disp (D) −33,948 $0 EDGAR
2025-03-07 ATRC Sell (S) −6,100 -$232.5K EDGAR
2025-03-05 ATRC Notice (144) −6,100 -$232.0K EDGAR
Showing 1–10 of 59
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.